SARS-CoV-2 a dagger to the aging heart

Researchers in Europe have shown that genes involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are expressed to a higher degree in older heart muscle cells (cardiomyocytes) than they are in younger cardiomyocytes.

The team found that genes encoding the proteins involved in host cell viral entry, including angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2) were upregulated in aged cardiomyocytes compared to young adult cardiomyocytes.

Risk factors for adverse outcomes following SARS-CoV-2 infection include age over 70 years and comorbidity, particularly cardiovascular disease.

Anthony Davenport (University of Cambridge) and colleagues say their findings could inform studies investigating experimental or currently available compounds to understand further how the protein pathways in cardiomyocytes contribute to disease outcomes in older patients with coronavirus disease 2019 (COVID-19).

A pre-print version of the paper is available on the server bioRxiv*, while the article undergoes peer review.

Schematic diagram of the key proteins predicted from RNASeq data to be expressed by human cardiomyocytes. We propose SARS-CoV-2 binds initially to ACE2 (with the ACE2/B0AT1 complex as a potential second entry site). TMPRSS2 priming of the spike protein S1 together with further protease activation by Cathepsins B and L facilitate viral cell entry and internalization by endocytosis. Furin may also have a role in this process. Internalization of the virus with ACE2 inhibits ACE2 carboxypeptidase activity that normally hydrolyses Ang-II, [Pyr1]-apelin-13 and des-Arg9-bradykinin. ADAM17, present on the cell surface, cleaves ACE2 to the soluble form that circulates in the plasma and could act as a decoy substrate for the virus. Levels of ADAM17 may be regulated by Ang-II and apelin acting via their respective G-protein coupled receptors.
Schematic diagram of the key proteins predicted from RNASeq data to be expressed by human cardiomyocytes. We propose SARS-CoV-2 binds initially to ACE2 (with the ACE2/B0AT1 complex as a potential second entry site). TMPRSS2 priming of the spike protein S1 together with further protease activation by Cathepsins B and L facilitates viral cell entry and internalization by endocytosis. Furin may also have a role in this process. Internalization of the virus with ACE2 inhibits ACE2 carboxypeptidase activity that normally hydrolyzes Ang-II, [Pyr1]-apelin-13, and des-Arg9-bradykinin. ADAM17, present on the cell surface, cleaves ACE2 to the soluble form that circulates in the plasma and could act as a decoy substrate for the virus. Levels of ADAM17 may be regulated by Ang-II and apelin acting via their respective G-protein coupled receptors.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The infection process

To infect host cells, the Spike protein on SARS-CoV-2 must bind ACE2 and undergo subsequent cleavage by TMPRSS2. This protease primes the Spike S1 subunit for the internalization of the virus. A second site on the S2 subunit is also cleaved by the enzyme furin. Once inside the cell, the virus undergoes endosomal processing by the cysteine proteases cathepsin L(CTSL) and cathepsin B (CTSB).

The role of ACE2

In cardiomyocytes, ACE2 converts the vasoconstrictor angiotensin II to the vasodilator angiotensin (1-7) and converts the inflammation-promoting peptide des-Arg9-bradykinin to inactive bradykinin (1-8).

Internalization of ACE2 by SARS-CoV-2 potentially counteracts the function of these metabolites in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and electrolyte balance.

Interestingly, ACE2 is also expressed in the gastrointestinal tract, where it associates with BOAT1, a protein that transports neutral amino acids across epithelial cell membranes. However, researchers do not yet know whether ACE2 is also co-expressed with BOAT1 in cardiomyocytes, which could serve as a crucial mechanism for viral entry.

The team’s hypothesis

Davenport and team hypothesized that differential expression of genes encoding the proteins involved in viral entry pathways in aged versus younger cardiomyocytes might explain why older people are particularly susceptible to the cardiovascular complications associated with COVID-19.

The researchers used RNA isolated from the cardiomyocyte nuclei of the left ventricle to make strand-specific RNA-sequencing libraries. The sequence data generated for five men, aged 19 to 25 years, were compared with those generated for five older men, aged 63 to 78 years, who had not been on medication and not shown any evidence of cardiovascular disease post-mortem.

The genes involved in viral entry were upregulated in aged cardiomyocytes

The expression of genes encoding proteins involved in viral entry was upregulated in the aged cardiomyocytes compared with the younger cardiomyocytes. The genes included ACE2, TMPRSS2, FURIN, CTSL, CTSB, and B0AT1, and their combined relative expression in cardiomyocytes correlated positively with age.

The researchers also found that the expression of Angiotensin II, ACE, Angiotensin II receptor type 1 (AGTR1), and Bradykinin receptor B1 (BDKBR1) all increased with age.

Generally, BDKBR1 is not expressed in muscle cells until expression is induced by inflammation and activated by des-Arg9-bradykinin, says the team.

The authors hope the findings can inform drug development studies

“Our results highlight SARS-CoV-2 related genes that have higher expression in aged compared with young adult cardiomyocytes,” write Davenport and team.

“These data may inform studies using selective enzyme inhibitors/antagonists, available as experimental compounds or clinically approved drugs e.g. remdesivir that has recently been rapidly accepted for compassionate use, to further understand the contribution of these pathways in human cardiomyocytes to disease outcome in COVID-19 patients.”

The researchers say drug candidates will need to be focused on preventing three main stages of infection (host cell viral entry, viral replication, and the ensuing tissue damage) in the heart tissue of older individuals - the age group most susceptible to COVID-19.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Mar 25 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2023, March 25). SARS-CoV-2 a dagger to the aging heart. News-Medical. Retrieved on June 20, 2024 from https://www.news-medical.net/news/20200709/SARS-CoV-2-a-dagger-to-the-aging-heart.aspx.

  • MLA

    Robertson, Sally. "SARS-CoV-2 a dagger to the aging heart". News-Medical. 20 June 2024. <https://www.news-medical.net/news/20200709/SARS-CoV-2-a-dagger-to-the-aging-heart.aspx>.

  • Chicago

    Robertson, Sally. "SARS-CoV-2 a dagger to the aging heart". News-Medical. https://www.news-medical.net/news/20200709/SARS-CoV-2-a-dagger-to-the-aging-heart.aspx. (accessed June 20, 2024).

  • Harvard

    Robertson, Sally. 2023. SARS-CoV-2 a dagger to the aging heart. News-Medical, viewed 20 June 2024, https://www.news-medical.net/news/20200709/SARS-CoV-2-a-dagger-to-the-aging-heart.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Open-access atlas unveils the molecular mechanisms of roundworm aging